Brief: APONTIS PHARMA Says Expects FY2023 Revenues Of EUR 42.6 Mln
02/05/2023 20:54
May 2 (Reuters) - Apontis Pharma AG APPHG.DE :
* EQS-ADHOC: APONTIS PHARMA AG ADJUSTS FORECAST FOR FISCAL
YEAR
2023
* APONTIS PHARMA AG SAYS EXPECTS FY REVENUES OF EUR 42.6
MILLION
(PREVIOUSLY: EUR 51.7 MILLION) AND EBITDA OF EUR -3.2 MILLION
(PREVIOUSLY: EUR 3.2 MILLION)
* APONTIS PHARMA-REASONS FOR CHANGES IN FORECAST REVENUES
AND
EARNINGS INCLUDE UNCERTAINTIES IN SUPPLY OF PRODUCT ATORIMIB BY
CONTRACTED MANUFACTURER
Source text for Eikon: ID:nEQ1Y74R7a
Further company coverage: APPHG.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apontis Pharma AG
See all newsBrief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
Brief: APONTIS PHARMA Q1 EBITDA EUR 1.3 Million
Brief: Apontis Pharma Says Zentiva AG Submits Formal Request To Carry Out A Merger
Brief: Zentiva Says Amendeds Offer To Acquire Each Outstanding Share Of Apontis Pharma In Cash By Waiving Condition Of A Minimum Acceptance
Brief: Apontis Pharma: Zentiva To Launch Voluntary Public Purchase Offer At EUR 10.00 Per Share